Xtandi enzalutamide: Phase III started

Astellas began the double-blind, placebo-controlled, international Phase III ARCHES trial to evaluate 160 mg

Read the full 142 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE